Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 2, 2026

China's Rare Earth Grip on the U.S. Military Is About to Break

View original at finance.yahoo.com
China's Rare Earth Grip on the U.S…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • REalloys expects to be the only company with a fully operational, non-Chinese, mine-to-magnet supply chain when Pentagon deadline arrives

    80% confidence
  • REalloys expects to become the largest producer of refined Dysprosium and Terbium outside of China

    80% confidence
  • REalloys expects to receive approximately 460 tonnes of defense-grade rare earth metals per year once Saskatchewan plant reaches full production

    80% confidence
  • Starting from zero, it would realistically take five to seven years to build what REalloys already has

    80% confidence
  • 1% reliance on China is 100% reliance on China - if any single input comes from Beijing, entire operation is one phone call away from shutting down

    80% confidence
  • REalloys expects scaled production to reach 18,000 tonnes per year of heavy rare earth permanent magnets

    80% confidence
  • It isn't rare earths that are critical to national security, it's the 'rare processing' industry

    80% confidence
  • Concentrates are commodities, materials are commitments

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com